Accéder au contenu
MilliporeSigma
Toutes les photos(2)

Documents

915408

Sigma-Aldrich

NanoFabTx PEGylated nanoparticle formulation screening kit

Synonyme(s) :

NanoFabTx reagent kit, Nanoparticle synthesis kit, PEGylated nanoformulations

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12161503
Nomenclature NACRES :
NA.23

Description

Kit components :
PEGPLGA-50L (912808-500mg)
PEGPLGA-75L (913049-500mg)
PEGPLA-L (913308-500mg)
PEGPCL-H (912549-500mg)
Stabilizer - P (913448-10g)

Materials screening kit, for synthesis of PEGylated polymeric nanoparticles

Niveau de qualité

Application(s)

advanced drug delivery

Température de stockage

2-8°C

Description générale

NanoFabTx PEGylated nanoparticle formulation screening kit contains optimized reagents and protocols for nanoprecipiation and microfluidic-based synthesis of polymer nanoparticles. The kit provides rationally selected PEGylated PLGA, PLA, and PCL polymers, which are widely used in drug delivery systems for controlled drug release of many different types of therapeutic molecules. This reagent kit can be combined with the NanoFabTx Microfluidic - nano device kit (Cat.No. 911593) for microfluidic synthesis of polymer nanoparticles 60 to 100 nm in size.

Application

NanoFabTx PEGylated nanoparticle formulation screening kit is designed for the synthesis of specifically sized, hydrophobic drug encapsulated biodegradable PEGylated polymer nanoparticles. Our specially designed PEGylated polymers result in nanoparticles with a PEG surface coating that reduces protein absorption and prolongs circulation time, leading to slow and sustained release of the encapsulated drug. The NanoFabTx PEGylated nanoparticle formulation screening kit enables nanoparticle optimization by selection of the right polymer to achieve the desired nanoparticle size, drug encapsulation, release kinetics, and stability in systemic circulation. This kit provides reagents and protocols for nanoprecipitation and microfluidics to synthesize 60 nm to 100 nm nanoparticles.

Caractéristiques et avantages

  • Provides step-by-step protocols, both for standard extrusion or microfluidic-based synthesis, developed and tested by our formulation scientists
  • Microfluidic formulation development for enhancing drug bioavailability
  • Flexible synthesis tool to create uniform and reproducible nanoparticles
  • Optimized to make nanoparticles from 60-100 nm
  • Includes 4 different PEGylated polymers to identify the optimal material

Informations légales

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Code de la classe de stockage

12 - Non Combustible Liquids


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

S Freiberg et al.
International journal of pharmaceutics, 282(1-2), 1-18 (2004-09-01)
Polymer microspheres can be employed to deliver medication in a rate-controlled and sometimes targeted manner. Medication is released from a microsphere by drug leaching from the polymer or by degradation of the polymer matrix. Since the rate of drug release
C Thomasin et al.
Journal of pharmaceutical sciences, 87(3), 269-275 (1998-04-02)
Phase separation (frequently called coacervation) of poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) is a classical method for drug microencapsulation. Here, attempts have been made to describe this process in the light of thermodynamics. Different PLA/PLGAs were dissolved in either dichloromethane or
K S Soppimath et al.
Journal of controlled release : official journal of the Controlled Release Society, 70(1-2), 1-20 (2001-02-13)
This review presents the most outstanding contributions in the field of biodegradable polymeric nanoparticles used as drug delivery systems. Methods of preparation, drug loading and drug release are covered. The most important findings on surface modification methods as well as
Robert F Pagels et al.
Journal of controlled release : official journal of the Controlled Release Society, 219, 519-535 (2015-09-12)
Biologically derived therapeutics, or biologics, are the most rapidly growing segment of the pharmaceutical marketplace. However, there are still unmet needs in improving the delivery of biologics. Injectable polymeric nanoparticles and microparticles capable of releasing proteins and peptides over time
Verónica Lassalle et al.
Macromolecular bioscience, 7(6), 767-783 (2007-06-02)
The controlled release of medicaments remains the most convenient way of drug delivery. Therefore, a wide variety of reports can be found in the open literature dealing with drug delivery systems. In particular, the use of nano- and microparticles devices

Articles

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTX kits enable precise drug delivery with lipid nanoparticles and liposomes for mRNA and nucleic acids.

Professor Robert K. Prud’homme introduces flash nanoprecipitation (FNP) for nanoparticle fabrication, which is a scalable, rapid mixing process for nanoparticle formulations.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique